"Lupin today is the fastest growing amongst the Top 5 Indian pharma companies. We are now poised to go for leadership"
	Mr. Shakti Chakraborty Group President India Region Formulations

Lupin’s Indian Formulations business continues to witness exemplary growth, where the Company continues to outpace and outperform the Indian Pharmaceutical Market (IPM). During FY 2010, Lupin's domestic formulations business outpaced and outperformed the Indian Pharmaceutical Market (IPM) and recorded sales of INR 13,502 million as compared to INR 11,412 million during FY 2009, a growth of 18%. Spurred by gains made this year, Lupin has today emerged as the fastest growing among the top 5 in the IPM, with an overall market share of 2.75% (ORG IMS Mar 2010).

Top 10 Lupin Brands

Product	Therapeutic segment	Ranking
TONACT	CVS	3
GLUCONORM	Anti Diabetic	2
RABLET	Gastro Intestinal	2
RCINEX	Anti-TB	1
AKT	Anti-TB	1
RAMISTAR	CVS	3
CLOPITAB	CVS	2
L-CIN	Levofloxacin	1
ODOXIL	Anti-Infective	1
DOXCEF	Cefpodoxime Solids	7

Lupin expanded its product portfolio with the introduction of a mix of branded and value added generics into the market place. The Company also added new therapy areas such as Nephrology and Osteoarthritis as it went about building market share in other existing segments. The Company's growth rates in some of the major therapeutic segments remain the best in the industry.

IRF Therapeutic Contribution (%)

Marketing Strategy & Execution
The Company's sales and marketing efforts, with sharp product and therapy focus has helped Lupin build brands that are market leaders. 6 Lupin products find a place amongst the Top 300 in the industry. During FY 2010, Lupin continued to witness growth across all key business divisions and therapy segments.

Therapeutic Segments	Market Growth Rate(%)	Lupin Growth Rate(%)
CVS  CVS	20	20
Anti TB	-2	7
Anti Asthma	21	34
Anti Infective	15	15
GI	17	20
CNS	20	36
Anti Diabetic	24	44
(ORG IMS Mar 10)